Litigation Details for Horizon Therapeutics USA Inc. v. Dr. Reddys Laboratories, Ltd. (D. Del. 2023)

Horizon Therapeutics USA Inc. v. Dr. Reddys Laboratories, Ltd. (D. Del. 2023)

Docket	1:23-cv-00623	Date Filed	2023-06-07
Court	District Court, D. Delaware	Date Terminated	2023-12-15
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Parties	DR. REDDYS LABORATORIES, LTD.
Patents	9,504,699
Link to Docket	External link to docket

Details for Horizon Therapeutics USA Inc. v. Dr. Reddys Laboratories, Ltd. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-06-07				External link to document

Horizon Therapeutics v. Dr. Reddy’s (1:23-cv-00623): Litigation Summary, Claims in Dispute, and Generic-Risk Impact

Last updated: July 16, 2026

Horizon Therapeutics USA Inc. v. Dr. Reddy’s Laboratories, Ltd. (U.S. District Court; case no. 1:23-cv-00623) is a patent infringement action tied to Dr. Reddy’s FDA generic entry for a Horizon-branded product. The matter’s commercial and generic-launch risk profile depends on the asserted patents’ expiration dates, whether the case targets formulation, method-of-use, or device/process claims, and the status of any Paragraph IV settlement terms.

What follows is a complete litigation summary and analysis grounded in the docket record identifiers provided in the case caption only. No further case-specific claim lists, schedule events, or settlement details are included because the underlying docket content is not provided in the prompt.

What is Horizon Therapeutics USA Inc. v. Dr. Reddy’s Laboratories 1:23-cv-00623 about?

Short answer: A U.S. patent infringement suit brought by Horizon Therapeutics USA Inc. against Dr. Reddy’s Laboratories, Ltd., docketed under 1:23-cv-00623, to block or limit FDA-generic market entry for an FDA-regulated Horizon product.

Which IP rights are typically asserted in this Horizon vs. Dr. Reddy’s fact pattern?

In Horizon-led generic-blocking actions against ANDA filers, the asserted estate usually falls into one or more of the following buckets:

• Composition/formulation patents (active ingredient + excipient system; specific polymorph/crystal form; coating; particle-size; stabilization system)
• Method-of-use patents (dosing regimens, patient populations, clinical endpoints, combination use)
• Manufacturing/process patents (steps that control impurities, crystallization outcomes, or scale-up parameters)
• Device or delivery system patents (where the product is associated with a specific delivery mechanism)

No asserted-patent list is provided in the prompt, so the litigation summary cannot be tied to specific patent numbers.

Which patents are asserted in 1:23-cv-00623 and what claims are at issue?

Short answer: The prompt does not include the complaint, asserted patent list, or claim chart elements. Without the docket’s pleadings, the asserted patents and claim scope cannot be stated.

How to interpret “claims in dispute” when you only have the docket number

Patent infringement cases in the ANDA/505(b)(2) context typically align claim scope to one or more of:

• Whether Dr. Reddy’s product meets the limitation of each independent claim (literal infringement)
• Whether design-around changes still satisfy claim elements (equivalents)
• Whether the asserted claims are invalid for anticipation/obviousness or unenforceable (inequitable conduct rarely dominates but can be pleaded)

Without the complaint’s actual asserted claims, the analysis cannot specify which of these theories is central.

What stage is the case in (filing date, motions, trial, settlement status)?

Short answer: The prompt provides only the case identifier and not the procedural history. The current litigation posture cannot be determined from the caption alone.

Typical milestones in ANDA patent cases

When docket text is available, investors and counsel track:

• Rule 16 scheduling order (early deadlines)
• Pleadings: complaint, answer, amended pleadings
• Invalidity: motions to dismiss (rare), summary judgment, Markman
• Claim construction and expert reports
• Daubert rulings
• Preliminary injunction motions (sometimes)
• Settlement: consent judgments or stipulated dismissal
• Post-judgment: appeal to the Federal Circuit (if applicable)

Those milestones cannot be anchored to dates or events here.

What is the Paragraph IV and FDA entry risk for Dr. Reddy’s in this litigation?

Short answer: The case name and context imply an ANDA-style patent dispute intended to influence FDA approval timing, but the specific FDA submission type (ANDA vs. 505(b)(2)), the paragraph certification(s), and the listed patents are not provided.

How courts weigh “generic entry risk” in these disputes

Once asserted-patent lists and FDA certifications are known, risk is driven by:

• Whether the court grants a stay or effective market exclusivity
• Whether claims are found infringing and valid
• Whether the generic is enjoined or can launch “at risk”
• Whether the case resolves via settlement with stipulated launch dates

No settlement terms, launch windows, or injunction scope can be stated without docket text.

When does Horizon’s product lose exclusivity, and how does that relate to 1:23-cv-00623?

Short answer: Exclusivity and patent-loss timelines cannot be calculated because the Horizon product and the relevant Orange Book/NDA or BLA reference are not identified in the prompt.

What usually determines the exclusivity date in Horizon cases

For small-molecule branded drugs, exclusivity usually includes:

• Patent expiry (utility patents)
• 180-day exclusivity for the first Paragraph IV ANDA filer (if applicable)
• Orphan drug exclusivity (if applicable)
• Pediatric exclusivity (if applicable)
• Regulatory exclusivities tied to supplements

For biologics, the framework shifts to:

• BLA reference product data exclusivity
• Biosimilar exclusivity and interchangeability milestones

Without the product name and the listed patents, a date-driven exclusivity timeline is not possible.

How strong is Horizon’s patent estate in this dispute?

Short answer: Strength cannot be assessed without the asserted patent numbers, independent claim language, prosecution history, and the invalidity theories pleaded in the complaint/answers.

What “strength” analysis requires in high-stakes Horizon v. Dr. Reddy’s cases

A robust estate-strength view typically evaluates:

• Claim breadth and claim construction vulnerability
• Whether patents are near the end of term or have remaining life
• Prior art density and whether key references were before the PTO
• Reexamination, terminal disclaimers, or licensing encumbrances
• Alignment between the infringement theory and the generic’s actual formulation/process

None of these inputs are present in the prompt.

What generic entry risks exist for Dr. Reddy’s if Horizon prevails or if Horizon loses?

Short answer: The prompt lacks the injunction posture, scheduling order, and any settlement. Risk scenarios cannot be quantified.

Scenario map that counsel uses once docket facts are available

Once asserted patents and court rulings are identified:

• If Horizon wins on validity and infringement: Dr. Reddy’s is blocked until patent expiration or a non-infringing workaround is cleared.
• If Horizon loses on invalidity: Dr. Reddy’s can typically launch sooner “at risk” or after FDA approval, subject to any further stays/appeals.
• If partially wins: the generic may launch for unadjudicated claims or redesign around.

No claim-by-claim outcomes are provided.

Does this case include a settlement agreement or stipulation?

Short answer: The prompt provides no settlement or dismissal documentation.

What settlement terms usually look like

When settlements occur in ANDA patent disputes, they commonly include:

• Stipulated launch date
• Payment terms (if disclosed)
• Consent to entry timing
• Dismissal with prejudice or partial dismissal

Those terms cannot be restated without the docket event.

Where is the case filed and what court rules apply?

Short answer: The case is filed in U.S. District Court under docket number 1:23-cv-00623. The prompt does not specify the district, judge, or magistrate allocation.

Why judge assignment matters for outcomes

Judge assignments often affect:

• Markman scheduling speed
• Claim construction approaches
• Timelines for Daubert and summary judgment
• Inclination to resolve on narrower grounds or broader construction

No judge name is provided in the prompt.

Key Takeaways

• Horizon Therapeutics USA Inc. v. Dr. Reddy’s Laboratories, Ltd. is a U.S. patent infringement case docketed as 1:23-cv-00623.
• The prompt does not include asserted patent numbers, FDA submission identifiers, claim construction outcomes, motion results, or settlement terms. As a result, this analysis cannot enumerate patents-at-issue, quantify expiration/exclusivity timing, or map court-stage milestones to generic launch risk.
• For decision-making (R&D, licensing, litigation, or investment exposure), the next operative facts required are the complaint’s asserted patent list and the docket’s procedural events; without those, no court-driven “strength” assessment or launch-date impact can be stated.

FAQs

1) What court rules govern 1:23-cv-00623?
Only the case docket identifier is provided; the district, judge, and applicable procedural orders are not included.

2) Are Paragraph IV certifications central to 1:23-cv-00623?
The prompt does not identify the FDA application type or the certification(s).

3) Which Horizon product is covered by the dispute?
The product is not stated in the prompt, so the associated Orange Book/BLA/NDA and exclusivity framework cannot be tied to the case.

4) What happens to Dr. Reddy’s launch timeline if Horizon wins?
A launch impact cannot be determined without the asserted patents, injunction posture, and any settlement or scheduling orders.

5) Is there a settlement that specifies a stipulated launch date?
No settlement or dismissal terms are provided in the prompt.

---

References (APA)

No sources were provided in the prompt, and no docket or FDA/Orange Book documents are cited.